No Data
Nuo Tai Bio (688076.SH): Subsidiary passes on-site inspection by the USA FDA.
On February 28, Gelonghui announced that its holding subsidiary Hangzhou Nuotai Nuohe Biomedical Technology Co., Ltd. (referred to as "Nuotai Nuohe") underwent an inspection by the USA Food and Drug Administration (referred to as "FDA") for cGMP (current Good Manufacturing Practice) from October 28, 2024, to November 1, 2024. Recently, Nuotai Nuohe received the Establishment Inspection Report (EIR) issued by the FDA, confirming that it successfully passed this cGMP site inspection.
NOTEC Biotech: NOTEC Biotech: 2024 Annual Results Report Announcement
Nootech: 2024 Annual Results Report Announcement
Does Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Have A Healthy Balance Sheet?
Jianghai Securities: The new diabetes drug Inzjen has issued the first prescription in the country. It is recommended to pay attention to the Industry Chain related to GLP-1 drugs.
With the continuous strengthening of domestic policies and the proactive response of Chinese Innovative Drugs companies, the ongoing market entry of related Innovative Drugs by Chinese pharmaceutical firms will challenge the global position of Semaglutide products.
Sinopep-Allsino Biopharmaceutical Passes GMP Inspections for APIs in South Korea, China
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%
